AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:BCPCBalchem Stock Price, Forecast & News

$93.15
-1.01 (-1.07 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$91.99
Now: $93.15
$95.98
50-Day Range
$86.30
MA: $94.59
$102.54
52-Week Range
$78.30
Now: $93.15
$113.93
Volume89,016 shs
Average Volume150,065 shs
Market Capitalization$3.01 billion
P/E Ratio37.41
Dividend Yield0.55%
Beta0.61
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include creamer and chocolate systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. Its Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The company's Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. It also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company's Industrial Products segment provides choline chloride derivatives for hydraulic fracturing of shale natural gas wells; and methylamines, which are building blocks for the manufacture of choline products, as well as used in industrial applications. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was founded in 1967 and is headquartered in New Hampton, New York.
Read More
Balchem logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars


Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
Current SymbolNASDAQ:BCPC
CUSIP05766520
CIK9326
Phone845-326-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$643.71 million
Cash Flow$4.60 per share
Book Value$23.12 per share

Profitability

Net Income$79.67 million

Miscellaneous

Employees1,424
Market Cap$3.01 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCPC and its competitors with MarketBeat's FREE daily newsletter.

Balchem (NASDAQ:BCPC) Frequently Asked Questions

How has Balchem's stock been impacted by COVID-19 (Coronavirus)?

Balchem's stock was trading at $89.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCPC stock has increased by 4.3% and is now trading at $93.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Balchem?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Balchem.

When is Balchem's next earnings date?

Balchem is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Balchem.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) posted its quarterly earnings data on Friday, May, 1st. The basic materials company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.22. The basic materials company had revenue of $174.44 million for the quarter, compared to analysts' expectations of $169.87 million. Balchem had a return on equity of 14.30% and a net margin of 12.20%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. View Balchem's earnings history.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem announced an annual dividend on Wednesday, December 18th. Investors of record on Monday, December 30th will be paid a dividend of $0.52 per share on Friday, January 17th. This represents a dividend yield of 0.51%. The ex-dividend date of this dividend is Friday, December 27th. This is a boost from Balchem's previous annual dividend of $0.47. View Balchem's dividend history.

What price target have analysts set for BCPC?

1 Wall Street analysts have issued 1 year price targets for Balchem's shares. Their forecasts range from $104.00 to $104.00. On average, they anticipate Balchem's stock price to reach $104.00 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View analysts' price targets for Balchem.

Has Balchem been receiving favorable news coverage?

News articles about BCPC stock have been trending negative recently, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Balchem earned a news impact score of -2.1 on InfoTrie's scale. They also gave news coverage about the basic materials company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Balchem.

Are investors shorting Balchem?

Balchem saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 493,100 shares, a decline of 8.7% from the June 15th total of 540,000 shares. Based on an average daily trading volume, of 173,600 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.5% of the shares of the company are short sold. View Balchem's Current Options Chain.

Who are some of Balchem's key competitors?

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Gilead Sciences (GILD), AbbVie (ABBV), CVS Health (CVS), Ecolab (ECL), Adobe (ADBE), Mastercard (MA), Altria Group (MO), NVIDIA (NVDA), Pfizer (PFE) and Starbucks (SBUX).

Who are Balchem's key executives?

Balchem's management team includes the following people:
  • Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 54)
  • Mr. William A. Backus CPA, Chief Accounting Officer (Age 53)
  • Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
  • Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 61)
  • Mr. Carl Martin Bengtsson, Chief Financial Officer

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

Who are Balchem's major shareholders?

Balchem's stock is owned by a number of retail and institutional investors. Top institutional investors include Bath Savings Trust Co (0.16%) and State of Alaska Department of Revenue (0.09%). Company insiders that own Balchem stock include Daniel E Knutson, David F Ludwig and Scott C Mason. View institutional ownership trends for Balchem.

Which major investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. View insider buying and selling activity for Balchem.

Which major investors are buying Balchem stock?

BCPC stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Balchem stock in the last two years include Daniel E Knutson, and Scott C Mason. View insider buying and selling activity for Balchem.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $93.15.

How big of a company is Balchem?

Balchem has a market capitalization of $3.01 billion and generates $643.71 million in revenue each year. The basic materials company earns $79.67 million in net income (profit) each year or $3.19 on an earnings per share basis. Balchem employs 1,424 workers across the globe.

What is Balchem's official website?

The official website for Balchem is www.balchem.com.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.